http://www.streetinsider.com Latest StreetInsider.com News Articles en-us Copyright 2026, StreetInsider.com rss@streetinsider.com (SI RSS) rss@streetinsider.com (SI RSS) Wed, 19 Aug 2026 16:05:00 -0400 http://blogs.law.harvard.edu/tech/rss http://www.streetinsider.com/images/rss_logo.gif http://www.streetinsider.com 143 28 0 1 2 3 21 22 23 Saturday Sunday http://www.streetinsider.com/SEC+Filings/Form++6-KA++++++Galmed+Pharmaceuticals++++For%3A+Jul+22/26950043.html si-local-file:///var/storage/secattach/20260819/26950043.html http://www.streetinsider.com/SEC+Filings/Form++6-KA++++++Galmed+Pharmaceuticals++++For%3A+Jul+22/26950043.html Wed, 19 Aug 2026 16:05:00 -0400 GLMD O.16140983 http://www.streetinsider.com/SEC+Filings/Form++6-KA++++++Galmed+Pharmaceuticals++++For%3A+Jul+22/26950043.html si-local-file:///var/storage/secattach/20260819/26950043.html http://www.streetinsider.com/SEC+Filings/Form++6-KA++++++Galmed+Pharmaceuticals++++For%3A+Jul+22/26950043.html Wed, 19 Aug 2026 16:05:00 -0400 GLMD O.16140983 http://www.streetinsider.com/SEC+Filings/Form++6-K++++++++Galmed+Pharmaceuticals++++For%3A+Aug+19/26947129.html si-local-file:///var/storage/secattach/20260819/26947129.html http://www.streetinsider.com/SEC+Filings/Form++6-K++++++++Galmed+Pharmaceuticals++++For%3A+Aug+19/26947129.html Wed, 19 Aug 2026 07:05:00 -0400 GLMD O.16140983 http://www.streetinsider.com/SEC+Filings/Form++6-K++++++++Galmed+Pharmaceuticals++++For%3A+Aug+19/26947129.html si-local-file:///var/storage/secattach/20260819/26947129.html http://www.streetinsider.com/SEC+Filings/Form++6-K++++++++Galmed+Pharmaceuticals++++For%3A+Aug+19/26947129.html Wed, 19 Aug 2026 07:05:00 -0400 GLMD O.16140983 http://www.streetinsider.com/Corporate+News/Galmed%27s+Colospan+reports+feasibility+data+on+tissue+assessment+tool/26947092.html <p>Colospan Ltd., a wholly owned subsidiary of Galmed Pharmaceuticals Ltd. (NASDAQ: GLMD), announced results from a feasibility study supporting the development of an intraoperative colon tissue quality assessment technology, according to a press release.</p><p>The prospective, single-arm study enrolled 32 colorectal cancer patients undergoing elective colorectal surgery at three medical centers in Israel. The study demonstrated that quantitative measurement of colon tissue compliance is technically feasible using a novel ex-vivo methodology. Measurements were obtained in all 32 patients with no reported measurement failures or procedure-related technical issues.</p><p>The technology is intended to provide surgeons with real-time quantitative data on tissue mechanical properties http://www.streetinsider.com/Corporate+News/Galmed%27s+Colospan+reports+feasibility+data+on+tissue+assessment+tool/26947092.html Wed, 19 Aug 2026 07:01:46 -0400 GLMD http://www.streetinsider.com/Press+Releases/Galmed+Announces+Successful+First-in-Human+Proof-of-Concept+Clinical+Study+Results+for+Colospan%27s+Novel+Intraoperative+Tissue+Assessment+Technology/26947041.html <div class="xn-content"> <ul type="disc"><li><b>The prospective, single-arm study enrolled 32 colorectal cancer patients at three leading clinical centers in <location value="LC/il" idsrc="xmltag.org" >Israel</location>. The primary objective was to demonstrate feasibility of intraoperative quantitative measurement of colon tissue quality.</b></li><li><b>The study establishes the clinical foundation for novel intraoperative tissue assessment technology, with an aim to expand Colospan's product pipeline with a second technology platform for Colorectal Surgery.</b></li><li><b>The new technology platform, which complements Colospan's CG-100 intraluminal bypass device, is designed to advance Galmed's strategy to build a leading innovative medtech and biotech company addressing unmet needs in GI oncology and colorectal surgery.</b></li></ul><p><span class="legendSpanClass"><location value="LU/il..ramgan" idsrc="xmltag.org" http://www.streetinsider.com/Press+Releases/Galmed+Announces+Successful+First-in-Human+Proof-of-Concept+Clinical+Study+Results+for+Colospan%27s+Novel+Intraoperative+Tissue+Assessment+Technology/26947041.html Wed, 19 Aug 2026 07:00:00 -0400 A.50216913 GLMD O.13816658 O.16140983 http://www.streetinsider.com/Press+Releases/Galmed+Announces+Successful+First-in-Human+Proof-of-Concept+Clinical+Study+Results+for+Colospan%27s+Novel+Intraoperative+Tissue+Assessment+Technology/26947041.html <div class="xn-content"> <ul type="disc"><li><b>The prospective, single-arm study enrolled 32 colorectal cancer patients at three leading clinical centers in <location value="LC/il" idsrc="xmltag.org" >Israel</location>. The primary objective was to demonstrate feasibility of intraoperative quantitative measurement of colon tissue quality.</b></li><li><b>The study establishes the clinical foundation for novel intraoperative tissue assessment technology, with an aim to expand Colospan's product pipeline with a second technology platform for Colorectal Surgery.</b></li><li><b>The new technology platform, which complements Colospan's CG-100 intraluminal bypass device, is designed to advance Galmed's strategy to build a leading innovative medtech and biotech company addressing unmet needs in GI oncology and colorectal surgery.</b></li></ul><p><span class="legendSpanClass"><location value="LU/il..ramgan" idsrc="xmltag.org" http://www.streetinsider.com/Press+Releases/Galmed+Announces+Successful+First-in-Human+Proof-of-Concept+Clinical+Study+Results+for+Colospan%27s+Novel+Intraoperative+Tissue+Assessment+Technology/26947041.html Wed, 19 Aug 2026 07:00:00 -0400 A.50216913 GLMD O.13816658 O.16140983 http://www.streetinsider.com/Press+Releases/Galmed+Announces+Successful+First-in-Human+Proof-of-Concept+Clinical+Study+Results+for+Colospan%27s+Novel+Intraoperative+Tissue+Assessment+Technology/26947041.html <div class="xn-content"> <ul type="disc"><li><b>The prospective, single-arm study enrolled 32 colorectal cancer patients at three leading clinical centers in <location value="LC/il" idsrc="xmltag.org" >Israel</location>. The primary objective was to demonstrate feasibility of intraoperative quantitative measurement of colon tissue quality.</b></li><li><b>The study establishes the clinical foundation for novel intraoperative tissue assessment technology, with an aim to expand Colospan's product pipeline with a second technology platform for Colorectal Surgery.</b></li><li><b>The new technology platform, which complements Colospan's CG-100 intraluminal bypass device, is designed to advance Galmed's strategy to build a leading innovative medtech and biotech company addressing unmet needs in GI oncology and colorectal surgery.</b></li></ul><p><span class="legendSpanClass"><location value="LU/il..ramgan" idsrc="xmltag.org" http://www.streetinsider.com/Press+Releases/Galmed+Announces+Successful+First-in-Human+Proof-of-Concept+Clinical+Study+Results+for+Colospan%27s+Novel+Intraoperative+Tissue+Assessment+Technology/26947041.html Wed, 19 Aug 2026 07:00:00 -0400 A.50216913 GLMD O.13816658 O.16140983 http://www.streetinsider.com/Press+Releases/Galmed+Announces+Successful+First-in-Human+Proof-of-Concept+Clinical+Study+Results+for+Colospan%27s+Novel+Intraoperative+Tissue+Assessment+Technology/26947041.html <div class="xn-content"> <ul type="disc"><li><b>The prospective, single-arm study enrolled 32 colorectal cancer patients at three leading clinical centers in <location value="LC/il" idsrc="xmltag.org" >Israel</location>. The primary objective was to demonstrate feasibility of intraoperative quantitative measurement of colon tissue quality.</b></li><li><b>The study establishes the clinical foundation for novel intraoperative tissue assessment technology, with an aim to expand Colospan's product pipeline with a second technology platform for Colorectal Surgery.</b></li><li><b>The new technology platform, which complements Colospan's CG-100 intraluminal bypass device, is designed to advance Galmed's strategy to build a leading innovative medtech and biotech company addressing unmet needs in GI oncology and colorectal surgery.</b></li></ul><p><span class="legendSpanClass"><location value="LU/il..ramgan" idsrc="xmltag.org" http://www.streetinsider.com/Press+Releases/Galmed+Announces+Successful+First-in-Human+Proof-of-Concept+Clinical+Study+Results+for+Colospan%27s+Novel+Intraoperative+Tissue+Assessment+Technology/26947041.html Wed, 19 Aug 2026 07:00:00 -0400 A.50216913 GLMD O.13816658 O.16140983 http://www.streetinsider.com/PRNewswire/Galmed+Announces+Successful+First-in-Human+Proof-of-Concept+Clinical+Study+Results+for+Colospan%27s+Novel+Intraoperative+Tissue+Assessment+Technology/26947041.html <div class="xn-content"> <ul type="disc"><li><b>The prospective, single-arm study enrolled 32 colorectal cancer patients at three leading clinical centers in <location value="LC/il" idsrc="xmltag.org" >Israel</location>. The primary objective was to demonstrate feasibility of intraoperative quantitative measurement of colon tissue quality.</b></li><li><b>The study establishes the clinical foundation for novel intraoperative tissue assessment technology, with an aim to expand Colospan's product pipeline with a second technology platform for Colorectal Surgery.</b></li><li><b>The new technology platform, which complements Colospan's CG-100 intraluminal bypass device, is designed to advance Galmed's strategy to build a leading innovative medtech and biotech company addressing unmet needs in GI oncology and colorectal surgery.</b></li></ul><p><span class="legendSpanClass"><location value="LU/il..ramgan" idsrc="xmltag.org" http://www.streetinsider.com/PRNewswire/Galmed+Announces+Successful+First-in-Human+Proof-of-Concept+Clinical+Study+Results+for+Colospan%27s+Novel+Intraoperative+Tissue+Assessment+Technology/26947041.html Wed, 19 Aug 2026 07:00:00 -0400 A.50216913 GLMD O.13816658 O.16140983 http://www.streetinsider.com/PRNewswire/Galmed+Announces+Successful+First-in-Human+Proof-of-Concept+Clinical+Study+Results+for+Colospan%27s+Novel+Intraoperative+Tissue+Assessment+Technology/26947041.html <div class="xn-content"> <ul type="disc"><li><b>The prospective, single-arm study enrolled 32 colorectal cancer patients at three leading clinical centers in <location value="LC/il" idsrc="xmltag.org" >Israel</location>. The primary objective was to demonstrate feasibility of intraoperative quantitative measurement of colon tissue quality.</b></li><li><b>The study establishes the clinical foundation for novel intraoperative tissue assessment technology, with an aim to expand Colospan's product pipeline with a second technology platform for Colorectal Surgery.</b></li><li><b>The new technology platform, which complements Colospan's CG-100 intraluminal bypass device, is designed to advance Galmed's strategy to build a leading innovative medtech and biotech company addressing unmet needs in GI oncology and colorectal surgery.</b></li></ul><p><span class="legendSpanClass"><location value="LU/il..ramgan" idsrc="xmltag.org" http://www.streetinsider.com/PRNewswire/Galmed+Announces+Successful+First-in-Human+Proof-of-Concept+Clinical+Study+Results+for+Colospan%27s+Novel+Intraoperative+Tissue+Assessment+Technology/26947041.html Wed, 19 Aug 2026 07:00:00 -0400 A.50216913 GLMD O.13816658 O.16140983 http://www.streetinsider.com/PRNewswire/Galmed+Announces+Successful+First-in-Human+Proof-of-Concept+Clinical+Study+Results+for+Colospan%27s+Novel+Intraoperative+Tissue+Assessment+Technology/26947041.html <div class="xn-content"> <ul type="disc"><li><b>The prospective, single-arm study enrolled 32 colorectal cancer patients at three leading clinical centers in <location value="LC/il" idsrc="xmltag.org" >Israel</location>. The primary objective was to demonstrate feasibility of intraoperative quantitative measurement of colon tissue quality.</b></li><li><b>The study establishes the clinical foundation for novel intraoperative tissue assessment technology, with an aim to expand Colospan's product pipeline with a second technology platform for Colorectal Surgery.</b></li><li><b>The new technology platform, which complements Colospan's CG-100 intraluminal bypass device, is designed to advance Galmed's strategy to build a leading innovative medtech and biotech company addressing unmet needs in GI oncology and colorectal surgery.</b></li></ul><p><span class="legendSpanClass"><location value="LU/il..ramgan" idsrc="xmltag.org" http://www.streetinsider.com/PRNewswire/Galmed+Announces+Successful+First-in-Human+Proof-of-Concept+Clinical+Study+Results+for+Colospan%27s+Novel+Intraoperative+Tissue+Assessment+Technology/26947041.html Wed, 19 Aug 2026 07:00:00 -0400 A.50216913 GLMD O.13816658 O.16140983 http://www.streetinsider.com/PRNewswire/Galmed+Announces+Successful+First-in-Human+Proof-of-Concept+Clinical+Study+Results+for+Colospan%27s+Novel+Intraoperative+Tissue+Assessment+Technology/26947041.html <div class="xn-content"> <ul type="disc"><li><b>The prospective, single-arm study enrolled 32 colorectal cancer patients at three leading clinical centers in <location value="LC/il" idsrc="xmltag.org" >Israel</location>. The primary objective was to demonstrate feasibility of intraoperative quantitative measurement of colon tissue quality.</b></li><li><b>The study establishes the clinical foundation for novel intraoperative tissue assessment technology, with an aim to expand Colospan's product pipeline with a second technology platform for Colorectal Surgery.</b></li><li><b>The new technology platform, which complements Colospan's CG-100 intraluminal bypass device, is designed to advance Galmed's strategy to build a leading innovative medtech and biotech company addressing unmet needs in GI oncology and colorectal surgery.</b></li></ul><p><span class="legendSpanClass"><location value="LU/il..ramgan" idsrc="xmltag.org" http://www.streetinsider.com/PRNewswire/Galmed+Announces+Successful+First-in-Human+Proof-of-Concept+Clinical+Study+Results+for+Colospan%27s+Novel+Intraoperative+Tissue+Assessment+Technology/26947041.html Wed, 19 Aug 2026 07:00:00 -0400 A.50216913 GLMD O.13816658 O.16140983 http://www.streetinsider.com/SEC+Filings/Form++6-K++++++++Galmed+Pharmaceuticals++++For%3A+Aug+17/26935873.html si-local-file:///var/storage/secattach/20260817/26935873.html http://www.streetinsider.com/SEC+Filings/Form++6-K++++++++Galmed+Pharmaceuticals++++For%3A+Aug+17/26935873.html Mon, 17 Aug 2026 09:20:00 -0400 GLMD O.16140983 http://www.streetinsider.com/SEC+Filings/Form++6-K++++++++Galmed+Pharmaceuticals++++For%3A+Aug+17/26935873.html si-local-file:///var/storage/secattach/20260817/26935873.html http://www.streetinsider.com/SEC+Filings/Form++6-K++++++++Galmed+Pharmaceuticals++++For%3A+Aug+17/26935873.html Mon, 17 Aug 2026 09:20:00 -0400 GLMD O.16140983 http://www.streetinsider.com/Corporate+News/Galmed%27s+Aramchol+shows+added+cell+death+in+prostate+cancer+study/26935847.html <p>Galmed Pharmaceuticals Ltd. (NASDAQ: GLMD) released pre-clinical data showing that its drug Aramchol, combined with enzalutamide (sold as Xtandi), produced a 3–4-fold increase in cell death compared with enzalutamide alone in a prostate cancer cell line model.</p><p>The study used the VCaP prostate cancer cell line, which features high expression of wild-type androgen receptors, the AR-V7 splice variant, and the TMPRSS2-ERG gene fusion, derived from a vertebral metastasis of a 59-year-old patient with metastatic castration-sensitive prostate cancer. According to the company's statement, the combined effect strengthened the longer both drugs were administered.</p><p>Aramchol is described as an SCD1 inhibitor. The company said http://www.streetinsider.com/Corporate+News/Galmed%27s+Aramchol+shows+added+cell+death+in+prostate+cancer+study/26935847.html Mon, 17 Aug 2026 09:15:40 -0400 GLMD http://www.streetinsider.com/Press+Releases/Galmed+Announces+First+Time+Results+in+Prostate+Oncology+Studies%3A+Aramchol+Demonstrates+3-4+Fold+Increase+in+Cell+Death+Compared+to+Enzalutamide+%28XTANDI%C2%AE%29+Alone+in+Prostate+Cancer+Models/26935837.html <div class="xn-content"> <ul type="disc"><li>Xtandi® (enzalutamide) is indicated as monotherapy for the treatment of patients with non-metastatic prostate cancer (nmCSPC) at high risk of metastasis and for the treatment of patients with metastatic prostate cancer (mCSPC) who are maintaining treatment with a GnRH analogue.</li><li>Global sales for Xtandi® (marketed by Astellas Pharma and Pfizer) reached approximately <money>$8 billion</money> and <money>$6 billion</money> globally in 2024 and 2025, respectively.</li><li>The main composition of matter patents for enzalutamide (sold as Xtandi) expire in 2026 in <location value="LR/eur" idsrc="xmltag.org" >Europe</location> and 2027 in <location value="LC/us" idsrc="xmltag.org" >the United States</location> (Patent US9126941 &amp; Patent US8183274) with a <location value="LC/us" http://www.streetinsider.com/Press+Releases/Galmed+Announces+First+Time+Results+in+Prostate+Oncology+Studies%3A+Aramchol+Demonstrates+3-4+Fold+Increase+in+Cell+Death+Compared+to+Enzalutamide+%28XTANDI%C2%AE%29+Alone+in+Prostate+Cancer+Models/26935837.html Mon, 17 Aug 2026 09:15:00 -0400 GLMD O.16140983 http://www.streetinsider.com/Press+Releases/Galmed+Announces+First+Time+Results+in+Prostate+Oncology+Studies%3A+Aramchol+Demonstrates+3-4+Fold+Increase+in+Cell+Death+Compared+to+Enzalutamide+%28XTANDI%C2%AE%29+Alone+in+Prostate+Cancer+Models/26935837.html <div class="xn-content"> <ul type="disc"><li>Xtandi® (enzalutamide) is indicated as monotherapy for the treatment of patients with non-metastatic prostate cancer (nmCSPC) at high risk of metastasis and for the treatment of patients with metastatic prostate cancer (mCSPC) who are maintaining treatment with a GnRH analogue.</li><li>Global sales for Xtandi® (marketed by Astellas Pharma and Pfizer) reached approximately <money>$8 billion</money> and <money>$6 billion</money> globally in 2024 and 2025, respectively.</li><li>The main composition of matter patents for enzalutamide (sold as Xtandi) expire in 2026 in <location value="LR/eur" idsrc="xmltag.org" >Europe</location> and 2027 in <location value="LC/us" idsrc="xmltag.org" >the United States</location> (Patent US9126941 &amp; Patent US8183274) with a <location value="LC/us" http://www.streetinsider.com/Press+Releases/Galmed+Announces+First+Time+Results+in+Prostate+Oncology+Studies%3A+Aramchol+Demonstrates+3-4+Fold+Increase+in+Cell+Death+Compared+to+Enzalutamide+%28XTANDI%C2%AE%29+Alone+in+Prostate+Cancer+Models/26935837.html Mon, 17 Aug 2026 09:15:00 -0400 GLMD O.16140983 http://www.streetinsider.com/PRNewswire/Galmed+Announces+First+Time+Results+in+Prostate+Oncology+Studies%3A+Aramchol+Demonstrates+3-4+Fold+Increase+in+Cell+Death+Compared+to+Enzalutamide+%28XTANDI%C2%AE%29+Alone+in+Prostate+Cancer+Models/26935837.html <div class="xn-content"> <ul type="disc"><li>Xtandi® (enzalutamide) is indicated as monotherapy for the treatment of patients with non-metastatic prostate cancer (nmCSPC) at high risk of metastasis and for the treatment of patients with metastatic prostate cancer (mCSPC) who are maintaining treatment with a GnRH analogue.</li><li>Global sales for Xtandi® (marketed by Astellas Pharma and Pfizer) reached approximately <money>$8 billion</money> and <money>$6 billion</money> globally in 2024 and 2025, respectively.</li><li>The main composition of matter patents for enzalutamide (sold as Xtandi) expire in 2026 in <location value="LR/eur" idsrc="xmltag.org" >Europe</location> and 2027 in <location value="LC/us" idsrc="xmltag.org" >the United States</location> (Patent US9126941 &amp; Patent US8183274) with a <location value="LC/us" http://www.streetinsider.com/PRNewswire/Galmed+Announces+First+Time+Results+in+Prostate+Oncology+Studies%3A+Aramchol+Demonstrates+3-4+Fold+Increase+in+Cell+Death+Compared+to+Enzalutamide+%28XTANDI%C2%AE%29+Alone+in+Prostate+Cancer+Models/26935837.html Mon, 17 Aug 2026 09:15:00 -0400 GLMD O.16140983 http://www.streetinsider.com/PRNewswire/Galmed+Announces+First+Time+Results+in+Prostate+Oncology+Studies%3A+Aramchol+Demonstrates+3-4+Fold+Increase+in+Cell+Death+Compared+to+Enzalutamide+%28XTANDI%C2%AE%29+Alone+in+Prostate+Cancer+Models/26935837.html <div class="xn-content"> <ul type="disc"><li>Xtandi® (enzalutamide) is indicated as monotherapy for the treatment of patients with non-metastatic prostate cancer (nmCSPC) at high risk of metastasis and for the treatment of patients with metastatic prostate cancer (mCSPC) who are maintaining treatment with a GnRH analogue.</li><li>Global sales for Xtandi® (marketed by Astellas Pharma and Pfizer) reached approximately <money>$8 billion</money> and <money>$6 billion</money> globally in 2024 and 2025, respectively.</li><li>The main composition of matter patents for enzalutamide (sold as Xtandi) expire in 2026 in <location value="LR/eur" idsrc="xmltag.org" >Europe</location> and 2027 in <location value="LC/us" idsrc="xmltag.org" >the United States</location> (Patent US9126941 &amp; Patent US8183274) with a <location value="LC/us" http://www.streetinsider.com/PRNewswire/Galmed+Announces+First+Time+Results+in+Prostate+Oncology+Studies%3A+Aramchol+Demonstrates+3-4+Fold+Increase+in+Cell+Death+Compared+to+Enzalutamide+%28XTANDI%C2%AE%29+Alone+in+Prostate+Cancer+Models/26935837.html Mon, 17 Aug 2026 09:15:00 -0400 GLMD O.16140983 http://www.streetinsider.com/SEC+Filings/Form++6-K++++++++Galmed+Pharmaceuticals++++For%3A+Aug+14/26931483.html si-local-file:///var/storage/secattach/20260814/26931483.html http://www.streetinsider.com/SEC+Filings/Form++6-K++++++++Galmed+Pharmaceuticals++++For%3A+Aug+14/26931483.html Fri, 14 Aug 2026 16:32:00 -0400 GLMD O.16140983 http://www.streetinsider.com/SEC+Filings/Form++6-K++++++++Galmed+Pharmaceuticals++++For%3A+Aug+14/26931483.html si-local-file:///var/storage/secattach/20260814/26931483.html http://www.streetinsider.com/SEC+Filings/Form++6-K++++++++Galmed+Pharmaceuticals++++For%3A+Aug+14/26931483.html Fri, 14 Aug 2026 16:32:00 -0400 GLMD O.16140983 http://www.streetinsider.com/SEC+Filings/Form++6-K++++++++Galmed+Pharmaceuticals++++For%3A+Jul+31/26850632.html si-local-file:///var/storage/secattach/20260731/26850632.html http://www.streetinsider.com/SEC+Filings/Form++6-K++++++++Galmed+Pharmaceuticals++++For%3A+Jul+31/26850632.html Fri, 31 Jul 2026 16:06:00 -0400 GLMD O.16140983 http://www.streetinsider.com/SEC+Filings/Form++6-K++++++++Galmed+Pharmaceuticals++++For%3A+Jul+31/26850632.html si-local-file:///var/storage/secattach/20260731/26850632.html http://www.streetinsider.com/SEC+Filings/Form++6-K++++++++Galmed+Pharmaceuticals++++For%3A+Jul+31/26850632.html Fri, 31 Jul 2026 16:06:00 -0400 GLMD O.16140983 http://www.streetinsider.com/SEC+Filings/Form++6-K++++++++Galmed+Pharmaceuticals++++For%3A+Jul+29/26834898.html si-local-file:///var/storage/secattach/20260729/26834898.html http://www.streetinsider.com/SEC+Filings/Form++6-K++++++++Galmed+Pharmaceuticals++++For%3A+Jul+29/26834898.html Wed, 29 Jul 2026 16:05:00 -0400 GLMD O.16140983